Wells Fargo lowered the firm’s price target on Wave Life Sciences (WVE) to $27 from $29 and keeps an Overweight rating on the shares. Ahead of multiple WVE-007 catalysts, the firm took a deep dive into INHBE, and came away expecting lean mass changes to plateau, and for further fat loss to drive weight loss. Lots to learn about dose, but Wells sees a path to a compelling profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Microsoft downgraded, Snap upgraded: Wall Street’s top analyst calls
- Wave Life Sciences initiated with a Buy at BofA
- Wave Life Sciences participates in a conference call with Cantor
- Wave Life Sciences: Regained WVE-006 Rights and De-Risked Regulatory Pathway Drive Compelling Buy-Rated AATD Opportunity
- Wave Life Sciences price target raised to $43 from $40 at Canaccord